Choose a country to view content specific to your location
Choose a country to view content specific to your location
Liquid biopsy is fast becoming the method of choice for cancer diagnosis in the field of precision medicine, allowing oncologists to choose a targeted therapy, monitor treatment resistance and detect minimal residual disease, without patients undergoing an invasive procedure. Liquid biopsy utilizes bodily fluids such as blood, stool, urine and saliva to detect cancer biomarkers earlier than conventional methods such as tissue biopsy. It is also useful to screen for drug-resistant subpopulations, micro-metastases, minimum residual disease and disease relapse. The non-invasive approach of liquid biopsies enables samples to be taken easily and repeatedly over the course of a patient’s treatment, overcoming the inherent shortcomings and risks of surgical tissue biopsies. This panel discussion will review how liquid biopsy is opening up new avenues in cancer detection and continuous monitoring for personalized cancer treatment, as well as the screening of cancer markers for therapeutic resistance. Four industrial leaders in the field of molecular diagnostics will come together to discuss the current status of liquid biopsy for cancer screening, as well as how modern technologies are changing the landscape of cancer detection and CDx.
Panelists:
Chris Sale (CEO, Nonacus, UK)
Shidong Jia, PhD (CEO, Predicine, USA)
Hongjun (Harry) Yang, PhD (Senior VP of CDx, DiaCarta, USA)
Florent Chang-Pi-Hin PhD (VP of R&D, Meridian Bioscience, USA)
Moderator:
Steve Hawkins, PhD (Product Marketing Manager, Meridian Bioscience)
Meridian offers diagnostic manufacturers the complete solution with over 3,000 antigens and antibodies covering more than 500 diseases and an extensive range of specialty qPCR/RT-qPCR master mixes and molecular enzymes all manufactured under ISO13485 regulations.
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our Privacy Statement.
